Screener
Ligand Pharmaceuticals LGND Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's operating lease liabilities (current)?
- Ligand Pharmaceuticals (LGND) reported operating lease liabilities (current) of $1.08M in Q2 2026.
- How has Ligand Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Ligand Pharmaceuticals's operating lease liabilities (current) decreased by 0.6% year-over-year, from $1.09M to $1.08M.
- What is the long-term trend for Ligand Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's operating lease liabilities (current) has grown at a -10.3% compound annual growth rate (CAGR), from $1.89M to $1.1M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Ligand Pharmaceuticals's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude